Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines about artificial intelligence. Everyone's talking about AI right now. But see, I've been talking about it for years.

I call it my AI Retirement Playbook. I recommend you check it out now.

Richard Daly Biography and Net Worth

President and CEO of Catalyst Pharmaceuticals

Richard J. Daly became our President and Chief Executive Officer on January 1, 2024 and has been a member of our Board of Directors since February 2015. Prior to joining Catalyst, from January 2022 until August 2023, Mr. Daly served as President of CARsgen Therapeutics Corporation, an emerging oncology company focused on developing CAR-T therapies for both liquid and solid tumors. From July 2018 through January 2022, Mr. Daly served as Chief Operating Officer of BeyondSpring Pharmaceuticals, a pre-commercial biotech company focused on oncology with assets in late Phase 3 clinical trials. Before joining BeyondSpring, (i) from February 2016 until July 2018 Mr. Daly served as Chairman and CEO of Neuralstem, Inc., a biopharmaceutical company focused on the development of central nervous system therapies based on its neuronal stem cell technology, (ii) from October 2014 until September 2016, Mr. Daly served as a partner of RavineRock Partners, a commercial consulting practice focused on biotech and pharmaceuticals, and (iii) from February 2013 until September 2014, Mr. Daly served as President of AstraZeneca US Diabetes. Mr. Daly served on the board of directors of Opiant Pharmaceuticals, and as a member of Opiant’s Compensation and Audit Committees, from 2018 until the sale of that company in 2023. From June 2015 until June 2018 Mr. Daly also served on the board of directors of Synergy Pharmaceuticals, where he chaired the Nominations/Corporate Governance Committee and was a member of the Compensation Committee. Mr. Daly received his Bachelor of Science in Microbiology from the University of Notre Dame in 1983 and his MBA from the Kellogg School of Management, Northwestern University in 1998.

What is Richard J. Daly's net worth?: The estimated net worth of Richard J. Daly is at least $2.30 million as of September 6th, 2024. Mr. Daly owns 105,094 shares of Catalyst Pharmaceuticals stock worth more than $2,296,304 as of December 16th. This net worth approximation does not reflect any other investments that Mr. Daly may own. Additionally, Mr. Daly receives an annual salary of $68,120.00 as President and CEO at Catalyst Pharmaceuticals. Learn More about Richard J. Daly's net worth.
How old is Richard J. Daly?: Mr. Daly is currently 63 years old. There are 6 older executives and no younger executives at Catalyst Pharmaceuticals. The oldest executive at Catalyst Pharmaceuticals is Dr. Gary Ingenito M.D., Ph.D., Chief Medical & Regulatory Officer, who is 68 years old. Learn More on Richard J. Daly's age.
What is Richard J. Daly's salary?: As the President and CEO of Catalyst Pharmaceuticals, Inc., Mr. Daly earns $68,120.00 per year. There are 5 executives that earn more than Mr. Daly. The highest earning executive at Catalyst Pharmaceuticals is Dr. Steven R. Miller Ph.D., Executive VP, COO & Chief Scientific Officer, who commands a salary of $884,700.00 per year. Learn More on Richard J. Daly's salary.
How do I contact Richard J. Daly?: The corporate mailing address for Mr. Daly and other Catalyst Pharmaceuticals executives is 355 ALHAMBRA CIRCLE SUITE 1250, CORAL GABLES FL, 33134. Catalyst Pharmaceuticals can also be reached via phone at (305) 420-3200 and via email at [email protected]. Learn More on Richard J. Daly's contact information.
Has Richard J. Daly been buying or selling shares of Catalyst Pharmaceuticals?: Richard J. Daly has not been actively trading shares of Catalyst Pharmaceuticals within the last three months. Most recently, Richard J. Daly sold 17,323 shares of the business's stock in a transaction on Tuesday, June 4th. The shares were sold at an average price of $15.97, for a transaction totalling $276,648.31. Following the completion of the sale, the chief executive officer now directly owns 234,824 shares of the company's stock, valued at $3,750,139.28. Learn More on Richard J. Daly's trading history.
Who are Catalyst Pharmaceuticals' active insiders?: Catalyst Pharmaceuticals' insider roster includes Philip Coelho (Director), Richard Daly (President and CEO), Jeffrey Del Carmen (EVP, Chief Commercial Officer), Donald Denkhaus (Director), Brian Elsbernd (Chief Legal and Compliance Officer), Alicia Grande (Vice President, Chief Financial Officer and Treasurer), Alicia Grande (CFO), Molly Harper (Director), Gary Ingenito (Insider), Patrick McEnany (CEO), Steve Miller (COO), Steven Miller (COO & Chief Scientific Officer ), and David Tierney (Director). Learn More on Catalyst Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Catalyst Pharmaceuticals?: In the last year, insiders at the biopharmaceutical company sold shares 12 times. They sold a total of 440,755 shares worth more than $8,352,888.44. The most recent insider tranaction occured on December, 10th when insider Steve Miller sold 50,000 shares worth more than $1,096,500.00. Insiders at Catalyst Pharmaceuticals own 11.0% of the company. Learn More about insider trades at Catalyst Pharmaceuticals.
Information on this page was last updated on 12/10/2024.

Richard J. Daly Insider Trading History at Catalyst Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
6/4/2024	Sell	17,323	$15.97	$276,648.31	234,824

Richard J. Daly Buying and Selling Activity at Catalyst Pharmaceuticals

Catalyst Pharmaceuticals Company Overview

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.

Today's Range

Now: $21.65

$21.33

$22.03

50 Day Range

MA: $21.65

$19.91

$23.93

2 Week Range

Now: $21.65

$13.12

$24.27

Volume

722,412 shs

Average Volume

1,167,456 shs

Market Capitalization

$2.58 billion

P/E Ratio

18.35

Dividend Yield

N/A

Beta

0.75

Most People Are Dead Wrong.

From Brownstone Research | Ad

I call it my AI Retirement Playbook. I recommend you check it out now.

Richard Daly Biography and Net Worth

What is Richard J. Daly's net worth?

How old is Richard J. Daly?

What is Richard J. Daly's salary?

How do I contact Richard J. Daly?

Has Richard J. Daly been buying or selling shares of Catalyst Pharmaceuticals?

Who are Catalyst Pharmaceuticals' active insiders?

Are insiders buying or selling shares of Catalyst Pharmaceuticals?